Ultragenyx Pharmaceutical Inc.
RARE
$29.78
$0.260.88%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 166.50M | 139.29M | 164.88M | 139.49M | 147.03M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 166.50M | 139.29M | 164.88M | 139.49M | 147.03M |
Cost of Revenue | 187.74M | 194.43M | 714.76M | 21.02M | 182.78M |
Gross Profit | -21.24M | -55.14M | -549.88M | 118.47M | -35.76M |
SG&A Expenses | 86.65M | 87.80M | 82.50M | 80.35M | 80.60M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 274.38M | 282.23M | 287.16M | 271.48M | 263.39M |
Operating Income | -107.89M | -142.94M | -122.28M | -131.99M | -116.36M |
Income Before Tax | -114.00M | -149.77M | -133.40M | -133.21M | -130.74M |
Income Tax Expenses | 947.00K | 1.31M | -19.00K | 303.00K | 858.00K |
Earnings from Continuing Operations | -114.95M | -151.08M | -133.39M | -133.52M | -131.60M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -114.95M | -151.08M | -133.39M | -133.52M | -131.60M |
EBIT | -107.89M | -142.94M | -122.28M | -131.99M | -116.36M |
EBITDA | -99.27M | -133.95M | -113.20M | -123.23M | -107.50M |
EPS Basic | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 |
Normalized Basic EPS | -0.72 | -0.97 | -0.86 | -0.88 | -0.92 |
EPS Diluted | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 |
Normalized Diluted EPS | -0.72 | -0.97 | -0.86 | -0.88 | -0.92 |
Average Basic Shares Outstanding | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M |
Average Diluted Shares Outstanding | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |